EGFR and small cell lung carcinoma: In our cohort of EGFR-mutant LUAD patients who developed resistance to EGFR-TKI therapy by undergoing histological transformation to SCLC (23 cases), the majority harbored EGFR mutations of type 19del (17/23; 73.9%), while a minority possessed L858R mutations (6/23;26.1%).